TEN Holdings, Inc. (XHLD)

Theseus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	3.12	3.5	3.72	4.81
Revenue Growth (YoY)	-21.35%	-5.78%	-22.63%	-
Cost of Revenue	0.56	0.65	0.56	0.74
Gross Profit	2.56	2.85	3.16	4.07
Selling, General & Admin	9.35	5.39	4.74	4.13
Operating Expenses	9.68	5.58	4.79	4.17
Operating Income	-7.12	-2.73	-1.63	-0.1
Interest Expense	-0.25	-0.21	-0.05	-
Other Non Operating Income (Expenses)	-0.03	-0.03	0.03	-0.01
Pretax Income	-7.4	-2.97	-1.65	-0.11
Income Tax Expense	-	-	0.04	7.55
Net Income	-7.4	-2.97	-1.69	-7.66
Net Income to Common	-7.4	-2.97	-1.69	-7.66
Shares Outstanding (Basic)	26	25	25	25
Shares Outstanding (Diluted)	26	25	25	25
Shares Change (YoY)	2.12%	0.06%	-	-
EPS (Basic)	-0.29	-0.12	-0.07	-0.31
EPS (Diluted)	-0.29	-0.12	-0.07	-0.31
Free Cash Flow	-8.72	-2.52	-0.29	0.04
Free Cash Flow Per Share	-0.34	-0.10	-0.01	0.00
Gross Margin	82.18%	81.39%	85.08%	84.69%
Operating Margin	-228.44%	-77.85%	-43.80%	-2.14%
Profit Margin	-237.53%	-84.70%	-45.39%	-159.41%
Free Cash Flow Margin	-279.81%	-72.00%	-7.80%	0.75%
EBITDA	-7.06	-2.67	-1.58	-0.06
EBITDA Margin	-226.71%	-76.31%	-42.43%	-1.21%
D&A For EBITDA	0.05	0.05	0.05	0.05
EBIT	-7.12	-2.73	-1.63	-0.1
EBIT Margin	-228.44%	-77.85%	-43.80%	-2.14%

Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q